<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02436538</url>
  </required_header>
  <id_info>
    <org_study_id>13546</org_study_id>
    <nct_id>NCT02436538</nct_id>
  </id_info>
  <brief_title>Correlation Between Serum Anti-Müllerian Hormone &amp; Müllerian Ducts Anomalies in Infertility</brief_title>
  <official_title>Correlation Between Serum Anti-Müllerian Hormone (AMH) Levels &amp; Müllerian Ducts Anomalies in Patients Undergoingintracytoplasmic Sperm Injection (ICSI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed M.Kamel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Egyptian IVF-ET Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-Müllerian hormone (AMH), also known as Müllerian inhibiting substance, is a dimeric
      glycoprotein that belongs to the transforming growth factor-beta family. It is involved in
      the regression of the Müllerian ducts during male fetal development. In the female, AMH is
      solely produced by the granulosa cells of preantral and small antral follicles, and regulates
      ovarian activity and follicular steroidogenesis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following approval of the internal review board of Egyptian IVF-ET center, a retrospective
      analysis will be undertaken where a detailed review of the patients files who underwent
      intracytoplasmic sperm injection (ICSI) trials starting January 2010 till January 2015 will
      be done.

      Patients with diagnosed mullerian anomalies will have their name , age ,duration of
      infertility, serum FSH, LH ,&amp; AMH levels recorded. The method of diagnosis (HSG,
      3D/ultrasonography, hysteroscopy, or laparoscopy) will also be documented.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of serum anti-Müllerian hormone (AMH) level with mullerian anomalies</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">226</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Mullerian duct anomalies</arm_group_label>
    <description>Anti Mullerian hormone level; Mullerian duct anomaly type</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anti Mullerian hormone level; Mullerian duct anomaly type</intervention_name>
    <description>Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels</description>
    <arm_group_label>Mullerian duct anomalies</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        female undergoing intraCytoplasmic sperm injection for treatment of infertility
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with diagnosed mullerian anomlies whether clinically or through imaging

        Exclusion Criteria:

          -  previous ovarian surgery

          -  ovarian drilling

          -  polycystic ovarian syndrome (PCOs).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yahia El-fassial, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>consultant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Egyptian IVF-ET Center</name>
      <address>
        <city>Cairo</city>
        <state>Maadi</state>
        <zip>3 st,161 Hadayek el Maadi</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Li HW, Ng EH, Wong BP, Anderson RA, Ho PC, Yeung WS. Correlation between three assay systems for anti-Müllerian hormone (AMH) determination. J Assist Reprod Genet. 2012 Dec;29(12):1443-6. doi: 10.1007/s10815-012-9880-1. Epub 2012 Nov 2.</citation>
    <PMID>23117477</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <last_update_submitted>December 3, 2016</last_update_submitted>
  <last_update_submitted_qc>December 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Ahmed M.Kamel</investigator_full_name>
    <investigator_title>lecturer Of obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>anti-Müllerian hormone (AMH)</keyword>
  <keyword>Mullerian anomalies</keyword>
  <keyword>ICSI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

